BlackRock Inc. raised its stake in Natus Medical Incorporated (NASDAQ:BABY) by 137,510.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,124,195 shares of the medical equipment provider’s stock after buying an additional 4,121,198 shares during the period. BlackRock Inc.’s holdings in Natus Medical were worth $161,874,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC raised its stake in shares of Natus Medical by 226.0% in the first quarter. Renaissance Technologies LLC now owns 149,294 shares of the medical equipment provider’s stock valued at $5,860,000 after buying an additional 103,494 shares during the last quarter. UBS Group AG raised its stake in shares of Natus Medical by 86.5% in the first quarter. UBS Group AG now owns 74,908 shares of the medical equipment provider’s stock valued at $2,940,000 after buying an additional 34,753 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Natus Medical by 2.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,401,566 shares of the medical equipment provider’s stock valued at $55,010,000 after buying an additional 38,125 shares during the last quarter. Kennedy Capital Management Inc. raised its stake in shares of Natus Medical by 12.9% in the first quarter. Kennedy Capital Management Inc. now owns 316,253 shares of the medical equipment provider’s stock valued at $12,413,000 after buying an additional 36,151 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Natus Medical by 6.5% in the first quarter. Geode Capital Management LLC now owns 416,752 shares of the medical equipment provider’s stock valued at $16,357,000 after buying an additional 25,444 shares during the last quarter. Hedge funds and other institutional investors own 95.66% of the company’s stock.
Natus Medical Incorporated (NASDAQ BABY) traded down 3.70% during midday trading on Friday, reaching $32.50. 360,673 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $36.21 and its 200 day moving average is $36.56. Natus Medical Incorporated has a 1-year low of $32.45 and a 1-year high of $44.39. The stock has a market cap of $1.06 billion, a P/E ratio of 56.33 and a beta of 0.93.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The firm had revenue of $122.20 million during the quarter, compared to the consensus estimate of $121.99 million. During the same quarter in the previous year, the company posted $0.39 earnings per share. The business’s revenue was up 27.3% on a year-over-year basis. Equities analysts anticipate that Natus Medical Incorporated will post $1.70 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/08/18/natus-medical-incorporated-nasdaqbaby-shares-bought-by-blackrock-inc-updated-updated-updated.html.
BABY has been the subject of several recent analyst reports. TheStreet cut shares of Natus Medical from a “b” rating to a “c+” rating in a report on Thursday, April 27th. Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. BidaskClub cut shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, Benchmark Co. restated a “buy” rating and set a $48.00 target price (down from $55.00) on shares of Natus Medical in a report on Monday, May 1st. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $45.00.
In other Natus Medical news, Director William M. Moore sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the sale, the director now owns 30,410 shares in the company, valued at $1,036,981. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Doris Engibous sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $32.68, for a total value of $163,400.00. Following the completion of the sale, the director now owns 22,650 shares of the company’s stock, valued at approximately $740,202. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
